Larry Tsai
Keine laufenden Positionen mehr
Profil
Larry Tsai worked as Vice President-Research & Development at Aeris Therapeutics LLC from 2002 to 2011.
He then worked as Chief Medical Officer at Tetraphase Pharmaceuticals, Inc. from 2018 to 2019.
Tsai received his undergraduate degree from Stanford University and his doctorate degree from Massachusetts Institute of Technology.
Ehemalige bekannte Positionen von Larry Tsai
| Unternehmen | Position | Ende |
|---|---|---|
| TETRAPHASE PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 24.06.2019 |
Aeris Therapeutics LLC
 Aeris Therapeutics LLC Medical SpecialtiesHealth Technology Aeris Therapeutics LLC develops therapies for patients with emphysema and other lung diseases. Its product AeriSeal System is designed to reduce lung volume in order to improve lung function and quality of life in patients with advanced emphysema. The company was founded in 2001 and it is headquartered in Woburn, MA. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2011 |
Ausbildung von Larry Tsai
| Stanford University | Undergraduate Degree |
| Massachusetts Institute of Technology | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Aeris Therapeutics LLC
Aeris Therapeutics LLC Medical SpecialtiesHealth Technology Aeris Therapeutics LLC develops therapies for patients with emphysema and other lung diseases. Its product AeriSeal System is designed to reduce lung volume in order to improve lung function and quality of life in patients with advanced emphysema. The company was founded in 2001 and it is headquartered in Woburn, MA. | Health Technology |
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
